Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein

A hybrid recombinant protein containing the amino acid sequences of the three most significant Pseudomonas aeruginosa antigens (membrane proteins OprF, OprI and toxoid aTox) was incorporated into a vaccine against Pseudomonas infection. Quality control of a hybrid recombinant protein and appro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. V. Soldatenkova, A. M. Kudryashova, N. F. Gavrilova, I. V. Yakovleva, O. V. Borisova, V. V. Sviridov, N. A. Mikhailova
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2020
Materias:	vaccine p. aeruginosa hybrid recombinant protein oprf-atox-opri enzyme-linked immunoassay Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/cc54e82b58554f6f990de72029ea75e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc54e82b58554f6f990de72029ea75e1
record_format	dspace
spelling	oai:doaj.org-article:cc54e82b58554f6f990de72029ea75e12021-11-18T08:03:50ZDevelopment of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein1563-06252313-741X10.15789/1563-0625-DOE-1906https://doaj.org/article/cc54e82b58554f6f990de72029ea75e12020-08-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1906https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XA hybrid recombinant protein containing the amino acid sequences of the three most significant Pseudomonas aeruginosa antigens (membrane proteins OprF, OprI and toxoid aTox) was incorporated into a vaccine against Pseudomonas infection. Quality control of a hybrid recombinant protein and appropriate vaccine includes determination of authentity and completeness of adsorption upon aluminum hydroxide adjuvant. The aim of our study was to develop techniques of quality control for a vaccine based on the hybrid OprF-aToxOprI recombinant protein specific to P. aeruginosa. Hybridomas secreting specific monoclonal antibodies for OprF-aTox-OprI were derived from the fusion of myeloma cells and murine spleen cells immunized with recombinant proteins P. aeruginosa. To produce sufficient quantities of antibodies, the hybrid cells were in vivo cultured in BALB/c mice. Supernates and ascite liquids were chromatographically purified with immune sorbent. Conjugation of antibodies with horseradish peroxidase was carried out according to P.K.Nakane. The hybrid OprF-aTox-OprI recombinant protein was detected by the solid-phase ELISA, using a panel of monoclonal antibodies and conjugates of monoclonal antibodies with horseradish peroxidase. Monoclonal antibodies were specific for different OprF-aTox-OprI epitopes. Titration assays containing OprF-aTox-OprI protein at 78 ng/ml to 5000 ng/ml were used as quantitative standards for calibration curves.To identify the recombinant protein OprF-aTox-OprI, 55 variants of of MAb pairs were tested. Limits of quantitative detection served for selection of most sensitive and specific ELISA variants. The quantitative detection limit was calculated for all 11 ELISA variants. Two ELISA variants with the highest sensitivity were selected for quality control of the hybrid recombinant protein. The limits of quantitative detection were, respectively, 2.9 and 13.6 ng/ml (0.0058 and 0.027% of the estimated antigen content in the vaccine) for the first and second ELISA variants. The first variant included a pair of monoclonal antibodies specific for the OprF and OprI epitopes, the second variant represented aTox and OprI epitopes. Two variants of ELISA were developed to detect the hybrid recombinant OprF-aTox-OprI protein. The first variant allows to determine the protein amount and to evaluate completeness of its adsorption on aluminum hydroxide. To confirm authenticity of the protein, both methods must be used, since they can detect all three antigens (OprF, aTox and OprI) which are present in the fusion protein.A. V. SoldatenkovaA. M. KudryashovaN. F. GavrilovaI. V. YakovlevaO. V. BorisovaV. V. SviridovN. A. MikhailovaSPb RAACIarticlevaccinep. aeruginosahybrid recombinant proteinoprf-atox-oprienzyme-linked immunoassayImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 22, Iss 4, Pp 805-810 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	vaccine p. aeruginosa hybrid recombinant protein oprf-atox-opri enzyme-linked immunoassay Immunologic diseases. Allergy RC581-607
spellingShingle	vaccine p. aeruginosa hybrid recombinant protein oprf-atox-opri enzyme-linked immunoassay Immunologic diseases. Allergy RC581-607 A. V. Soldatenkova A. M. Kudryashova N. F. Gavrilova I. V. Yakovleva O. V. Borisova V. V. Sviridov N. A. Mikhailova Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
description	A hybrid recombinant protein containing the amino acid sequences of the three most significant Pseudomonas aeruginosa antigens (membrane proteins OprF, OprI and toxoid aTox) was incorporated into a vaccine against Pseudomonas infection. Quality control of a hybrid recombinant protein and appropriate vaccine includes determination of authentity and completeness of adsorption upon aluminum hydroxide adjuvant. The aim of our study was to develop techniques of quality control for a vaccine based on the hybrid OprF-aToxOprI recombinant protein specific to P. aeruginosa. Hybridomas secreting specific monoclonal antibodies for OprF-aTox-OprI were derived from the fusion of myeloma cells and murine spleen cells immunized with recombinant proteins P. aeruginosa. To produce sufficient quantities of antibodies, the hybrid cells were in vivo cultured in BALB/c mice. Supernates and ascite liquids were chromatographically purified with immune sorbent. Conjugation of antibodies with horseradish peroxidase was carried out according to P.K.Nakane. The hybrid OprF-aTox-OprI recombinant protein was detected by the solid-phase ELISA, using a panel of monoclonal antibodies and conjugates of monoclonal antibodies with horseradish peroxidase. Monoclonal antibodies were specific for different OprF-aTox-OprI epitopes. Titration assays containing OprF-aTox-OprI protein at 78 ng/ml to 5000 ng/ml were used as quantitative standards for calibration curves.To identify the recombinant protein OprF-aTox-OprI, 55 variants of of MAb pairs were tested. Limits of quantitative detection served for selection of most sensitive and specific ELISA variants. The quantitative detection limit was calculated for all 11 ELISA variants. Two ELISA variants with the highest sensitivity were selected for quality control of the hybrid recombinant protein. The limits of quantitative detection were, respectively, 2.9 and 13.6 ng/ml (0.0058 and 0.027% of the estimated antigen content in the vaccine) for the first and second ELISA variants. The first variant included a pair of monoclonal antibodies specific for the OprF and OprI epitopes, the second variant represented aTox and OprI epitopes. Two variants of ELISA were developed to detect the hybrid recombinant OprF-aTox-OprI protein. The first variant allows to determine the protein amount and to evaluate completeness of its adsorption on aluminum hydroxide. To confirm authenticity of the protein, both methods must be used, since they can detect all three antigens (OprF, aTox and OprI) which are present in the fusion protein.
format	article
author	A. V. Soldatenkova A. M. Kudryashova N. F. Gavrilova I. V. Yakovleva O. V. Borisova V. V. Sviridov N. A. Mikhailova
author_facet	A. V. Soldatenkova A. M. Kudryashova N. F. Gavrilova I. V. Yakovleva O. V. Borisova V. V. Sviridov N. A. Mikhailova
author_sort	A. V. Soldatenkova
title	Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
title_short	Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
title_full	Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
title_fullStr	Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
title_full_unstemmed	Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
title_sort	development of elisa test for the quality control of pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein
publisher	SPb RAACI
publishDate	2020
url	https://doaj.org/article/cc54e82b58554f6f990de72029ea75e1
work_keys_str_mv	AT avsoldatenkova developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein AT amkudryashova developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein AT nfgavrilova developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein AT ivyakovleva developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein AT ovborisova developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein AT vvsviridov developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein AT namikhailova developmentofelisatestforthequalitycontrolofpseudomonasaeruginosarecombinantvaccinebasedonthehybridrecombinantprotein
_version_	1718422316148326400

Development of ELISA test for the quality control of Pseudomonas aeruginosa recombinant vaccine based on the hybrid recombinant protein

Ejemplares similares